Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.34
-$0.02(-0.40%)
At close: 4:00 PM EST
$0.34
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$0.20 - $2.37
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.88M
Market Cap
$49.50M
Enterprise Value$13.26M
Total Cash (Recent Filing)$36.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding159,618,600
10 Day Avg. Volume982,169
30 Day Avg. Volume1,882,988
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue26.52
Enterprise Value/Gross Profit212.10
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$3.00Price Target Upside782.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$14.28M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt provides durable financial flexibility for a clinical-stage biotech. With no interest burden, the company can prioritize R&D and partnerships, lowering bankruptcy risk and making equity or partnership funding more effective to sustain long-term clinical programs.
High Gross Margins On RevenueHigh gross margins indicate favorable product-level economics if clinical assets are commercialized. For a biotech, strong margins support scalable profitability once fixed R&D and SG&A are controlled, improving long-term operating leverage as revenue ramps from successful approvals or partner deals.
Financing Flexibility And Board ContinuityRenewed share issuance authority and reappointment of directors create structural continuity and funding optionality. The board can raise equity to fund multi-year clinical trials or strike partnerships without needing immediate debt, supporting program continuity and strategic execution over the coming years.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows deplete cash reserves and shorten runway, forcing frequent external financing or partnership monetization. This structural cash burn increases execution risk for multi-year development programs and constrains resource allocation to priority assets.
Minimal Revenue; Large Ongoing LossesVery low recurring revenue coupled with large net losses means core operations are not self-sustaining. Until clinical assets reach commercialization or large partnering milestones occur, the business will likely remain loss-making, pressuring cash needs and shareholder returns over the medium term.
Declining Equity Base & Dilution RiskA shrinking equity base reduces the balance-sheet buffer while recurring financing needs likely lead to share issuance. Expanded non-pre-emptive issuance authority structurally raises dilution risk for existing holders and signals dependence on equity funding to sustain development, affecting long-term returns.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma’s price range in the past 12 months?
Mereo Biopharma lowest stock price was $0.20 and its highest was $2.37 in the past 12 months.
What is Mereo Biopharma’s market cap?
Mereo Biopharma’s market cap is $49.50M.
When is Mereo Biopharma’s upcoming earnings report date?
Mereo Biopharma’s upcoming earnings report date is Aug 18, 2026 which is in 30 days.
How were Mereo Biopharma’s earnings last quarter?
Mereo Biopharma released its earnings results on May 12, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Mereo Biopharma overvalued?
According to Wall Street analysts Mereo Biopharma’s price is currently Undervalued.
Does Mereo Biopharma pay dividends?
Mereo Biopharma does not currently pay dividends.
What is Mereo Biopharma’s EPS estimate?
Mereo Biopharma’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma have?
Mereo Biopharma has 159,618,600 shares outstanding.
What happened to Mereo Biopharma’s price movement after its last earnings report?
Mereo Biopharma reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 1.653%.
Which hedge fund is a major shareholder of Mereo Biopharma?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (782.35% Upside)
$3.00 (782.35% Upside)
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.58%
12-Months-Change
Fundamentals
Return on Equity
-81.25%
Trailing 12-Months
Asset Growth
-40.55%
Trailing 12-Months
Company Description
Mereo Biopharma
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$3.00
▲(782.35% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
37.27% Other Institutional Investors
61.74% Public Companies and
Individual Investors